Is sandostatin used for vipoma?

Is Sandostatin used for VIPoma?

Sandostatin is FDA-approved for the symptomatic treatment of VIPoma, a rare neuroendocrine tumor that secretes excessive vasoactive intestinal peptide (VIP). It relieves symptoms such as severe diarrhea and dehydration by inhibiting hormone secretion.

How does Sandostatin work in VIPoma?

Sandostatin contains octreotide, a synthetic somatostatin analogue. It binds to somatostatin receptors on tumor cells and normal cells, slowing hormone production and reducing blood flow to the tumor. This mechanism reduces VIP levels in plasma and volume of watery diarrhea episodes.

What are the clinical data on Sandostatin for VIPoma?

Clinical reports show rapid control of diarrhea within days of treatment. Older studies document 80-90% of patients achieving symptomatic relief, 50% showing partial tumor regression, and lower plasma VIP levels. [1]

What side effects are patients asking about?

Common side effects include injection site reactions, gallstones, hyperglycemia, and GI upset. Long-term use may require monitoring for gallbladder disease and glucose levels. Patients often report flatulence and abdominal pain as daily concerns.

When does Sandostatin's patent expire?

Sandostatin's composition-of-matter patent expired decades ago. Generic octreotide acetate is widely available. The reference listed drug is still owned by Novartis, but many generics compete on price. [2]

Who makes Sandostatin?

Novartis manufactures the brand-name Sandostatin. Generics are produced by multiple companies such as Sun Pharma, Fresenius Kabi, and Mylan.